Key result
Adherent patients receiving three doses of inclisiran on-schedule achieved a mean maximal LDL-C reduction of 38.7% and a time-adjusted average reduction of 33% between days 90 and 450.
Why the study?
Does inclisiran reduce LDL-C in a real-world clinical practice setting among adherent patients?
Observational (n=16,531)
Yes
Does inclisiran reduce LDL-C in a real-world clinical practice setting among adherent patients?
In real-world practice, adherence to the inclisiran dosing schedule is suboptimal (28.2% received 3 doses on schedule), but adherent patients achieve significant LDL-C reductions comparable to clinical trials, especially those with higher baseline LDL-C.
No takes yet. Share an insight, caveat, or question.
Suboptimal adherence limits real-world inclisiran benefit; leaves open strategies to improve dosing persistence while supporting RCT efficacy.
Hwang et al. (2025) conducted an observational in Elevated LDL-C (n=16,531). Inclisiran was evaluated on Maximal percentage reduction in LDL-C compared with baseline between days 90-450. Adherent patients receiving three doses of inclisiran on-schedule achieved a mean maximal LDL-C reduction of 38.7% and a time-adjusted average reduction of 33% between days 90 and 450.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: